Roche’s investigational candidate RG7716 showed “clinically meaningful” and “statistically significant” improvements in gaining visual acuity in patients with diabetic macular edema (DME) compared to the VEGF inhibitor Lucentis® (ranibizumab)
Johnson & Johnson has initiated its first JLABS incubator in Europe called JLABS @ BE. It will be the 10th JLABS in the world. JLABS @ BE will accommodate up to 30 life sciences startups which aim innovation in the healthcare space including biotech, pharmaceuticals, medical devices, consumer and healthtech sectors.
New treatment option- anti-CGRP drugs, to prevent a migraine is expected to reach the market in 2018. Allergan’s anti-CGRP candidate, ubrogepant – first oral candidate showed positive outcomes in late-stage clinical development.